Please use this identifier to cite or link to this item:
https://hdl.handle.net/20.500.12530/25475
Title: | Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients. | |
Authors: | ||
Mesh: | ||
Issue Date: | 2016 | |
Citation: | PLoS ONE.2016;(11)8:e0161484 | |
Abstract: | Antiangiogenic therapies for glioblastoma (GBM) such as bevacizumab (BVZ), have been unable to extend survival in large patient cohorts. However, a subset of patients having angiogenesis-dependent tumors might benefit from these therapies. Currently, there are no biomarkers allowing to discriminate responders from non-responders before the start of the therapy. | |
PMID: | 27557121 | |
URI: | https://hdl.handle.net/20.500.12530/25475 | |
Rights: | openAccess | |
Appears in Collections: | Hospitales > H. U. 12 de Octubre > Artículos | |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
PMC4996463.pdf | 911.35 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.